You are here

Pharmaceuticals and Healthcare

The business of vital innovation

The pharmaceutical and healthcare sector is one of the world’s most vital and innovative.

Against a backdrop of technological change and an increasing and aging population, we partner with our clients to help them achieve their goals, capitalise on opportunities and navigate uncertainty.

Combining deep scientific, technical and strategic knowledge we help our clients by providing the commercial nous, experience and range of services that only a large international professional services firm can offer, to anticipate and deliver innovative and value-enhancing solutions.

Recent Experience

Hoffmann La-Roche AG and Roche Products Limited (Roche)

Advising F. Hoffmann La-Roche AG and Roche Products Limited (Roche) in a significant High Court victory against Pfizer, in an action concerning Avastin®, Roche's blockbuster treatment for various forms of cancer. The action centred on whether a UK court should grant a form of negative declaratory relief known as an "Arrow declaration" in circumstances where our client had no relevant patent rights in the UK, and the claimant (Pfizer) intended to use the declarations and judgment solely for the purposes of influencing foreign courts.

Mylan Laboratories

Advising in its significant victory in a SIAC arbitration commenced by Phosphagenics in Singapore arising from licensing and research agreements, in which Phosphagenics claimed damages of over US$ 300 million

Aurobindo Pharma

Advising on its acquisition of Apotex's commercial operations across five European countries. The transaction includes a portfolio of over 200 prescription drugs and 88 OTC products and an additional pipeline of over 20 products

A global innovator pharmaceuticals company

Advising in an ICC arbitration seated in Singapore. This concerned a dispute with another global pharmaceuticals company arising out of a co-promotion agreement. Following a two-week merits hearing, our client won a significant award.

AbbVie

Advising AbbVie on its proposed US$55 billion takeover of Shire, a FTSE-100 pharmaceutical company

Claris Life Sciences Limited

Acting for Claris Life Sciences Limited on the sale of its Global Generic Injectables Business to Baxter for US$ 625 million

Diverse knowledge and in-depth expertise